Company research
Apimeds Pharmaceuticals US, Inc.
CIK 1894525Updated Sep 24, 2026
SecurityAPUS · NYSE_AMERICAN · equity
APUS price & chart
Loading TradingView…
AMEX:APUS on TradingView ↗About the company
We are a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally administered bee venom-based toxin which potentially exhibits diverse therapeutic effects. Apitox is currently marketed and sold by Apimeds Inc. (“Apimeds Korea”) in the South Korea as “Apitoxin.” Apimeds US is not associated with the market, sale and revenues generated from Apitoxin in South Korea, and Apitoxin has not been approved by the U.S. Food and Drug Administration (the “FDA”) for any indication. Apimeds is currently developing Apitox as a potential osteoarthritis (“OA”) treatment for patients with knee pain who failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics.
In the news
Recent filings
Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Items 3.03, 5.03, 9.01
Entry into a Material Definitive Agreement · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 1.01, 5.02, 9.01
Entry into a Material Definitive Agreement
Items 1.01, 9.01
10-Q filing
Other Events
Items 8.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| ASSETS | |||
| AssetsUSD | 164,183,736Source | 13,057Source | 422,076Source |
| Property, Plant and Equipment, NetUSD | 51,626Source | — | — |
| Current assets: | |||
| Cash and Cash Equivalents, at Carrying ValueUSD | 1,636,655Source | 3,455Source | 410,481Source |
| Assets, CurrentUSD | 13,983,859Source | 13,057Source | 422,076Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,298,704Source | 9,602Source | 11,595Source |
| Operating Lease, Right-of-Use AssetUSD | 187,395Source | — | — |
| LIABILITIES AND EQUITY | |||
| LiabilitiesUSD | 10,835,909Source | 1,371,178Source | 390,207Source |
| Stockholders’ equity: | |||
| Preferred Stock, Value, IssuedUSD | 74,770Source | — | — |
| Common Stock, Value, IssuedUSD | 125,760Source | 79,039Source | 79,039Source |
| Additional Paid in CapitalUSD | 163,540,358Source | 2,954,764Source | 2,954,764Source |
| Retained Earnings (Accumulated Deficit)USD | -10,393,061Source | -4,391,924Source | -3,001,934Source |
| Stockholders' Equity Attributable to ParentUSD | 153,347,827Source | -1,358,121Source | 31,869Source |
| Liabilities and EquityUSD | 164,183,736Source | 13,057Source | 422,076Source |
| Current liabilities: | |||
| Liabilities, CurrentUSD | 10,706,455Source | 1,024,334Source | 123,316Source |
| Operating Lease, Liability, CurrentUSD | 39,578Source | — | — |
| Operating Lease, Liability, NoncurrentUSD | 129,454Source | — | — |
| Additional Financial Items | |||
| Accrued Liabilities, CurrentUSD | 500,000Source | — | — |
| Short-term InvestmentsUSD | 2,000,000Source | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Cash flows from operating activities: | |||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 1,565,806Source | — | 69,993Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -8,925,777Source | -733,526Source | -627,790Source |
| Cash flows from investing activities: | |||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | -15,345Source | — | — |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -10,060,351Source | — | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | 57,333Source | — | — |
| Cash flows from financing activities: | |||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 20,619,327Source | 326,500Source | 1,032,100Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 9,636,655Source | 3,455Source | 410,481Source |
| Additional Financial Items | |||
| Accretion ExpenseUSD | 283,010Source | 79,953Source | 5,069Source |
| Share-based Payment Arrangement, ExpenseUSD | 2,044,186Source | 0Source | 69,993Source |
| DepreciationUSD | 5,706Source | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -521Source | — | — |
| General and Administrative ExpenseUSD | 10,279,981Source | 1,275,095Source | 648,892Source |
| InterestExpenseNonoperatingUSD | 283,011Source | 117,719Source | 38,069Source |
| Investment Income, InterestUSD | 107,595Source | 2,824Source | 7,811Source |
| Net Income (Loss) Attributable to ParentUSD | -6,001,137Source | -1,389,990Source | -777,694Source |
| Nonoperating Income (Expense)USD | 5,911,425Source | -114,895Source | -30,258Source |
| Operating ExpensesUSD | 11,912,562Source | — | — |
| Proceeds from Issuance of Common StockUSD | 11,629,727Source | — | 1,055,000Source |
| Realized Investment Gains (Losses)USD | 1,822,115Source | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Operating Income (Loss)USD | -11,912,562Source | -1,275,095Source | -747,436Source |
| Net Income (Loss) Attributable to ParentUSD | -6,001,137Source | -1,389,990Source | -777,694Source |
| Earnings Per Share, BasicUSD per share | -0.55Source | -0.18Source | -0.17Source |
| Earnings Per Share, DilutedUSD per share | -0.55Source | -0.18Source | -0.17Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 10,881,907Source | 7,903,850Source | 4,598,265Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 10,881,907Source | — | — |
| Interest Expense (non-operating)USD | 283,011Source | 117,719Source | 38,069Source |
| Additional Financial Items | |||
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -521Source | — | — |
| General and Administrative ExpenseUSD | 10,279,981Source | 1,275,095Source | 648,892Source |
| Investment Income, InterestUSD | 107,595Source | 2,824Source | 7,811Source |
| Nonoperating Income (Expense)USD | 5,911,425Source | -114,895Source | -30,258Source |
| Operating ExpensesUSD | 11,912,562Source | — | — |
| Realized Investment Gains (Losses)USD | 1,822,115Source | — | — |
| Research and Development ExpenseUSD | 1,632,581Source | — | 98,544Source |
Offerings
Registration 333-282324
- Gross proceeds
- 13500000.0
- Net proceeds
- 12555000.0
- Deal price
- 4.0
- Shares
- 3375000
- Offering price
- $4.00
- Ticker
- APUS
Filing attachments
ea028720301ex99-1_apimeds.htm · 8-K · 2026-04-22
EX-99.1 2 ea028720301ex99-1_apimeds.htm PRESS RELEASE DATED APRIL 21, 2026 Exhibit 99.1 Apimeds Pharmaceuticals Receives Notice from NYSE Regulation Regarding Late Filing of Annual Report Matawan, N.J. April 22, 2026 -- (NYSE American: APUS) Apimeds Pharmaceuticals US, Inc. (the “Company”), today announced that on April 17, 2026, it received a notice of non-compliance (the “Notice”) with the continued listing standards set forth in Section 1007 of the Company Guide of NYSE American LLC (“N…
Read attachment ↗ea028355001ex99-1.htm · 8-K · 2026-03-26
EX-99.1 2 ea028355001ex99-1.htm PRESS RELEASE ISSUED BY MINDWAVE INNOVATIONS INC. DATED MARCH 24, 2026 Exhibit 99.1 Apimeds Pharmaceuticals US Inc. Announces Material Breach of Merger Agreement by Inscobee Inc. (KS:006490) and Apimeds Inc.; Prepares Filing Emergency Action in Delaware Court of Chancery MATAWAN, N.J. & SEOUL, South Korea - March 24, 2026 MindWave Innovations Inc., a Delaware corporation and wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (“APUS” or the “Compan…
Read attachment ↗ea026780701ex4-1_apimeds.htm · 8-K · 2025-12-02
EX-4.1 4 ea026780701ex4-1_apimeds.htm FORM OF NOTE Exhibit 4.1 FORM OF SENIOR CONVERTIBLE NOTE NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITI…
Read attachment ↗ea026780701ex4-2_apimeds.htm · 8-K · 2025-12-02
EX-4.2 5 ea026780701ex4-2_apimeds.htm WARRANT ISSUED TO E.F. HUTTON & CO. LLC, DATED DECEMBER 1, 2025 Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE …
Read attachment ↗ea026780701ex99-1_apimeds.htm · 8-K · 2025-12-02
EX-99.1 10 ea026780701ex99-1_apimeds.htm PRESS RELEASE, DATED DECEMBER 1, 2025 Exhibit 99.1 Apimeds and MindWave Announce Merger, Integrating Biotech Growth with AI-Driven Digital Treasury Yield Generation Backed by $100M PIPE Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) announced a merger with MindWave Innovations Inc, uniting Apimeds’ late-stage, non-opioid pain-management biologic portfolio with MindWave’s AI-driven Bitcoin treasury, digital asset yield generation, and $NILA-p…
Read attachment ↗ea024916001ex99-1_apimeds.htm · 8-K · 2025-07-16
EX-99.1 2 ea024916001ex99-1_apimeds.htm PRESS RELEASE DATED JULY 15, 2025 Exhibit 99.1 Apimeds Expands Leadership Team with Dr. Susan Kramer to Lead Product Development and Brian Peters to Lead its ai² Division MATAWAN, N.J., July 15, 2025--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), a clinical-stage biopharmaceutical company developing Apitox, an intradermally administered, bee venom-based therapeutic, today announced two key addit…
Read attachment ↗